UMIN-CTR Clinical Trial

Recruitment status Terminated
Unique ID issued by UMIN UMIN000002964
Receipt No. R000003436
Official scientific title of the study Prospective, randomized, open-label, clinical trial comparing fibrate monotherapy and fibrate-ezetimibe combination therapy on progression of atherosclerotic plaques, endothelial function, and markers for anti-inflammatory properties/obesity/antioxidative properties
Date of disclosure of the study information 2010/01/03
Last modified on 2018/05/24 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Prospective, randomized, open-label, clinical trial comparing fibrate monotherapy and fibrate-ezetimibe combination therapy on progression of atherosclerotic plaques, endothelial function, and markers for anti-inflammatory properties/obesity/antioxidative properties
Title of the study (Brief title) Prospective, randomized, open-label, clinical trial comparing fibrate monotherapy and fibrate-ezetimibe combination therapy
Region
Japan

Condition
Condition dyslipidemia
Classification by specialty
Cardiology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Comparison of fibrate monotherapy and fibrate-ezetimibe combination therapy on progression of atherosclerotic plaques, endothelial function, and markers for anti-inflammatory properties/obesity/antioxidative properties
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase IV

Assessment
Primary outcomes Area of atherosclerotic plaques in aorta detected by magnetic resonance imaging (MRI), 12/24 months after randomization
Serum lipids (total/LDL/HDL-cholesterol, triglycerides), 6/12/24 months after randomization
Flow-mediated vasodilation in forearm, 6 months after randomization
Heparin-releasable EC-SOD levels, 6 months after randomization
Key secondary outcomes Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria), 6/12/24 months after randomization

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit
Blinding Open -but assessor(s) are blinded
Control No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Administration of ezetimibe
Interventions/Control_2 No medication
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria 1) Dyslipidemic patients under treatment with fibrates, whose LDL-C levels do not meet those recommended by Japan Atherosclerosis Society Guidelines for prevention of Atherosclerotic Cardiovascular Disease.
2) Patients who have aortic atherosclerotic plaques detected by MRI
3) Outpatients
4) Subjects who gave written informed consent
Key exclusion criteria 1) Allergy against ezetimibe
2) Under treatment with statins
3) Poor-controlled hypertension (DBP>110 mmHg)
4) Poor-controlled diabetes (HbA1c>10.0 %)
5) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months
6) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits.
7) Chronic renal failure (serum creatinine>2.0 mg/dl)
8) Malignancies or other diseases with poor prognosis
9) Pregnant
10) Subjects whose doctor in charge do not agree to join the trial
Target sample size 60

Research contact person
Name of lead principal investigator Katsunori Ikewaki
Organization National Defense Medical College
Division name Department of Internal Medicine I
Address 3-2 Namiki, Tokorozawa, JAPAN 359-8513
TEL 04-2995-1597
Email katsunorike@ndmc.ac.jp

Public contact
Name of contact person Makoto Ayaori
Organization National Defense Medical College
Division name Department of Internal Medicine I
Address 3-2 Namiki, Tokorozawa, JAPAN 359-8513
TEL 04-2995-1597
Homepage URL
Email ayaori@ndmc.ac.jp

Sponsor
Institute National Defense Medical College
Institute
Department

Funding Source
Organization Foundation for Promotion of Defense Medicine
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 防衛医科大学校

Other administrative information
Date of disclosure of the study information
2010 Year 01 Month 03 Day

Progress
Recruitment status Terminated
Date of protocol fixation
2009 Year 12 Month 20 Day
Anticipated trial start date
2010 Year 01 Month 01 Day
Last follow-up date
2012 Year 12 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2010 Year 01 Month 02 Day
Last modified on
2018 Year 05 Month 24 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003436